Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the 340B drug discount program.
First-term U.S. Rep. Matt Rosendale (R-Mont.) isn’t a member of the House Energy & Commerce Committee with primary jurisdiction over the 340B program, much less a majority member, so his Drug Pricing Transparency and Accountability Act, H.R. 5463, faces long odds of passage.
Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the drug discount program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
